Q-omics provides the consensus-scored FIGNL2 profile across patient tissues and cancer cell-line models. FIGNL2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FIGNL2 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, FIGNL2 RNA expression shows 16,876 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCS, KICH, and KIRP as cancer lineages where FIGNL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FIGNL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FIGNL2 survival associations across molecular data types. FIGNL2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FIGNL2 RNA expression–survival associations across cancer types. High FIGNL2 expression shows unfavorable associations in UCEC and LGG, but favorable associations in UCS, PAAD, LUAD and THYM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for FIGNL2 RNA expression.
This table summarizes FIGNL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FIGNL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FIGNL2 shows lower tumor expression in KICH, BRCA and KIRC and higher tumor expression in HNSC, LIHC and STAD. The KICH box plot shows higher FIGNL2 RNA expression in normal versus tumor tissue (log2 FC = −2.400, t-test p < 0.001).
This table shows molecular features associated with FIGNL2 in patient tissues and cancer cell lines. In patient samples, FIGNL2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, FIGNL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
